Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis - PubMed

4 hours ago

Tirzepatide, a dual agonist of GIP and GLP-1 receptors, shows promise in reducing cardiovascular mortality and worsening heart failure events in patients with obesity-related HFpEF.
A meta-analysis of five studies involving 47,710 patients with HFpEF and BMI ≥ 30 kg/m² found Tirzepatide significantly reduced the composite outcome of cardiovascular mortality and worsening heart failure compared to standard therapy (HR 0.50; 95% CI: 0.42-0.60; p < 0.001).
Tirzepatide also showed a significant reduction in heart failure exacerbation events alone versus standard therapy (HR 0.75; p = 0.04), but no significant difference was observed when compared to semaglutide (HR 0.95; p = 0.31).
No significant differences were found in heart failure hospitalization and all-cause mortality between Tirzepatide and standard therapy or semaglutide.
The study highlights the need for more head-to-head comparisons between Tirzepatide and semaglutide in HFpEF patients.
Adverse drug reactions were not significantly different between the treatment groups.

Hasty Briefsbeta